Table 5. Logistic regression of RECIST NCT response.

Variable	Category	Odd ratio	OR (95% CI)	P value
Age	>60 (vs. ≤60)	1.06	0.33–3.39	0.928
Gender	Male (vs. female)	3.26	0.47–22.87	0.234
Smoking	Current/former smoker (vs. never smoker)	0.24	0.04–1.48	0.125
Pathology	Adenocarcinoma (A)	1		0.975
	Squamous (vs. A)	1.43	0.30–6.91	0.658
	Adenosquamous (vs. A)	2.65	0–inf	1.000
	Large cell (vs. A)	1.58	0.07–38.33	0.780
Clinical T stage	I	1		0.865
	II (vs. stage I)	0.64	0.18–2.28	0.491
	III (vs. stage I)	0.00	0–inf	0.999
	IV (vs. stage I)	3.01	0.04–224.19	0.616
Clinical N stage	0	1		0.935
	I (vs. stage 0)	1.10	0.03–35.98	0.957
	II (vs. stage 0)	2.06	0.04–97.90	0.714
Central/peripheral	peripheral (vs. central)	0.56	0.11–2.92	0.489

RECIST, response evaluation criteria in solid tumors; NCT, neoadjuvant chemotherapy.